SavedAdd your journal

Journals / Akdeniz Tıp Dergisi / 2023 / Cilt: 9 Sayı: 2

WHICH TREATMENT SHOULD BE SELECTED FOR THE OPTIMUM APPROACH TO PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH DRIVER MUTATION? A CASE REPORT AND LITERATURE REVIEW

Birden Fazla Sürücü Mutasyonlu Küçük Hücre Olmayan Akciğer Kanserli Hastalarda Optimum Yaklaşım İçin Hangi Tedavi Seçilmelidir? Bir Vaka Raporu ve Literatür İncelemesi

Onur Yazdan BALÇIK
Esin OKTAY
Gizem DÖNMEZ YALÇIN
Pages
226–230
Publication Date
2023-05-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, randomized studies are needed to clarify which patients with concurrent mutations may benefit from chemotherapy or related tki.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We present a case of concomitant c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) and fusion in non small cell lung cancer (NSCLC) in a 59-year-old patient and review the treatment efficacy of co-mutations.
📊
Key Findings & Data:The choice of the treatment and its effectiveness with rare co-mutations is a subject of considerable interest.
💡
Conclusion & Impact:However, randomized studies are needed to clarify which patients with concurrent mutations may benefit from chemotherapy or related tki.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:ALK · ROS · MUTASYON

Abstract

We present a case of concomitant c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) and fusion in non small cell lung cancer (NSCLC) in a 59-year-old patient and review the treatment efficacy of co-mutations. The choice of the treatment and its effectiveness with rare co-mutations is a subject of considerable interest. This review will provide clues to the optimal treatment approach to NSCLC patients with more than one driver mutations. However, randomized studies are needed to clarify which patients with concurrent mutations may benefit from chemotherapy or related tki.

Özet

59 yaşındaki bir hastada küçük hücreli olmayan akciğer kanserinde (KHDAK) bir anaplastik lenfoma kinaz (ALK) ve c-ros onkogen 1 (ROS1) füzyonu vakasını sunuyoruz ve ko-mutasyonların tedavi etkinliğini gözden geçiriyoruz. Tedavinin seçimi ve nadir ko-mutasyonlarla etkinliği oldukça ilgi çeken bir konudur. Bu derleme, birden fazla sürücü mutasyonu olan KHDAK hastalarına optimal tedavi yaklaşımına dair ipuçları sağlayacaktır. Bununla birlikte, hangi hastaların uygun TKI veya kemoterapiden fayda görebileceğini netleştirmek için randomize çalışmalara ihtiyaç vardır. Anahtar Kelimeler: Akciğer, Mutasyon, Alk, Ros

🔖

Cite This Article

BALÇIK, O. Y., OKTAY, E., YALÇIN, G. D. (2023). WHICH TREATMENT SHOULD BE SELECTED FOR THE OPTIMUM APPROACH TO PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH DRIVER MUTATION? A CASE REPORT AND LITERATURE REVIEW. Akdeniz Tıp Dergisi, Cilt: 9 Sayı: 2, 226–230. https://ajindex.com/articles/936851

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011;12(8):735-742
  2. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010;11(2):121-128
  3. Mok TS, Wu Y, Thongprasert S, Yang, C, Chu D, Saijo N, Sunpaweravong P, Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 2009;361(10): 947-957
  4. Zhang X, Zhang S, Yang Z, Yang J, Zhou Q, Yin Y, An S. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer, 2010;9(1):1-12
  5. An SJ, Chen ZH, Su J, Zhang WZ, Zhong WZ, Yang JL, Zhou Q. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One, 2012;7(6): e40109
  6. Cote ML, Haddad R, Edwards DJ, Atikukke G, Gadgeel S, Soubabi AO, Leonardo F. Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thorac Oncol, 2011;6(3): 627-30
  7. Kohno T, Takashi N, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, Goto K. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res, 2015;4(2):156
  8. Mazières J, Zalcman G, Crino L, Biondani P, Barlesi F, Filleron T, Dingemans AM. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol, 2015;33(9):992-999
  9. Peters S, Mok TS, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, Perol M. Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC. J Clin Oncol, 2020;38(15):9518-9518
  10. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2018;378(2):113-125
  11. Shen L, Qiang T, Li Z, Ding D, Yu Y, Lu S. First-line crizotinib